T&S advises GNA on contract with State of Bavaria for developing Corona PCR rapid test
December 29, 2020
Patent Attorney Dr. Raphael Tautz at Tautz & Schuhmacher Patent Attorneys has advised the molecular diagnostics company GNA Biosolutions GmbH located at Martinsried near Munich regarding intellectual property aspects on the drafting and negotiation of an agreement with the Bavarian State Ministry of Economics for the development of a novel PCR rapid test system for the detection of the SARS-CoV-2 virus.
The portable GNA Octea PCR rapid test system developed under the contract allows for detecting the pathogen in just 40 minutes including sample collection, processing and evaluation, without sacrificing accuracy.
GNA Biosolutions GmbH has received Emergency Use Authorisation from the German Health Authority BfArM for the GNA Octea SARS-CoV-2 test system.
Further information can be found on the manufacturer's homepage:
Consultant at Tautz & Schuhmacher Patentanwälte:
Patent Attorney Dr. Raphael Tautz
Image source: GNA Biosolutions GmbH. The image is protected by copyright.